117 related articles for article (PubMed ID: 9454886)
21. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies.
Geradts J; Hruban RH; Schutte M; Kern SE; Maynard R
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):71-9. PubMed ID: 10937052
[TBL] [Abstract][Full Text] [Related]
22. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.
Saxena A; Robertson JT; Ali IU
Oncogene; 1996 Aug; 13(3):661-4. PubMed ID: 8760309
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetic alterations in radiation-induced astrocytomas.
Brat DJ; James CD; Jedlicka AE; Connolly DC; Chang E; Castellani RJ; Schmid M; Schiller M; Carson DA; Burger PC
Am J Pathol; 1999 May; 154(5):1431-8. PubMed ID: 10329596
[TBL] [Abstract][Full Text] [Related]
24. Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.
Calvano JE; Rush EB; Tan LK; Rosen PP; Borgen PI; Van Zee KJ
Ann Surg Oncol; 1997; 4(5):416-20. PubMed ID: 9259969
[TBL] [Abstract][Full Text] [Related]
25. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.
El-Naggar AK; Lai S; Clayman G; Lee JK; Luna MA; Goepfert H; Batsakis JG
Am J Pathol; 1997 Dec; 151(6):1767-74. PubMed ID: 9403727
[TBL] [Abstract][Full Text] [Related]
26. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
[TBL] [Abstract][Full Text] [Related]
27. Frequent homozygous deletion of p16/CDKN2A gene in malignant gliomas of Iranian patients.
Zadeh MD; Amini R; Firoozray M; Derakhshandeh-Peykar P
Pak J Biol Sci; 2007 Dec; 10(23):4246-50. PubMed ID: 19086579
[TBL] [Abstract][Full Text] [Related]
28. [Homozygous deletion of CDKN2/p16 gene in lung cancers].
Su C; Ye Y; Cao X; Shan X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Oct; 16(5):315-7. PubMed ID: 10514540
[TBL] [Abstract][Full Text] [Related]
29. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours.
Schmidt EE; Ichimura K; Messerle KR; Goike HM; Collins VP
Br J Cancer; 1997; 75(1):2-8. PubMed ID: 9000591
[TBL] [Abstract][Full Text] [Related]
30. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
31. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
32. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex.
Alves MK; Faria MH; Neves Filho EH; Ferrasi AC; Pardini MI; de Moraes Filho MO; Rabenhorst SH
Int J Surg; 2013; 11(7):549-53. PubMed ID: 23721661
[TBL] [Abstract][Full Text] [Related]
34. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
35. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.
Muscarella P; Melvin WS; Fisher WE; Foor J; Ellison EC; Herman JG; Schirmer WJ; Hitchcock CL; DeYoung BR; Weghorst CM
Cancer Res; 1998 Jan; 58(2):237-40. PubMed ID: 9443399
[TBL] [Abstract][Full Text] [Related]
36. Frequent alterations of cell-cycle regulators in astrocytic tumors as detected by molecular genetic and immunohistochemical analyses.
Nakamura M; Konishi N; Hiasa Y; Tsunoda S; Nakase H; Tsuzuki T; Aoki H; Sakitani H; Inui T; Sakaki T
Brain Tumor Pathol; 1998; 15(2):83-8. PubMed ID: 10328544
[TBL] [Abstract][Full Text] [Related]
37. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.
Heesters MA; Koudstaal J; Go KG; Molenaar WM
J Neurooncol; 1999; 44(3):255-66. PubMed ID: 10720205
[TBL] [Abstract][Full Text] [Related]
38. Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR.
Perry A; Nobori T; Ru N; Anderl K; Borell TJ; Mohapatra G; Feuerstein BG; Jenkins RB; Carson DA
J Neuropathol Exp Neurol; 1997 Sep; 56(9):999-1008. PubMed ID: 9291941
[TBL] [Abstract][Full Text] [Related]
39. Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ
Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
